American Journal of Epidemiology Vol. 155, No. 10 : 883-890
Copyright © 2002 by The Johns Hopkins University School of Hygiene and Public Health
HUMAN GENOME EPIDEMIOLOGY (HuGE) REVIEW |
Androgen Receptor CAG Repeats and Prostate Cancer
From the Department of Epidemiology and Biostatistics, Case Western Reserve University, 2109 Adelbert Road, Cleveland, OH 44106-4945 (e-mail: witte{at}darwin.cwru.edu).
ABSTRACT
Prostate cancer is the most common nonskin malignancy and the second leading cause of cancer deaths among men in the United States. Prostate cancer ([Mendelian Inheritance in Man 176807]) has a complex etiology; presently, age, ethnicity, and family history are the most consistently reported risk factors associated with disease. Other potential risk and protective factors have also been suggested. Androgen, acting through the androgen receptor (AR) is helpful in preserving the normal function and structure of the prostate. The AR ([Mendelian Inheritance in Man 313700]) is a structurally conserved member of the nuclear receptor superfamily of ligand-activated transcription factors. Androgens, such as testosterone, are strong tumor promoters, and work with the AR to augment the effect of any carcinogens present and stimulate cell division. The CAG repeats encode long glutamine homopolymeric amino acid chains in the amino-terminal domain of the AR gene. The authors focus on CAG repeat length because recent research suggests that men with shorter AR CAG lengths (e.g., 
22 repeats) are at a greater risk of developing prostate cancer than are those with longer variants. Among populations studied to date, African Americans appear to have the highest frequency of short CAG repeats. Several potential interactions have also been explored, including molecular interactions, androgen deprivation therapy, and prostate-specific antigen expression. CAG repeat length can be determined with high sensitivity and specificity. Presently, there is no recommended population screening for AR CAG repeat length.
epidemiology; prostatic neoplasms; receptors, androgen; trinucleotide repeats
Abbreviations: AR, androgen receptor; BPH, benign prostatic hypertrophy; CI, confidence interval; PCR, polymerase chain reaction; SBMA, spinal and bulbar muscular atrophy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. A Hughes and C. L Acerini Factors controlling testis descent Eur. J. Endocrinol., December 1, 2008; 159(suppl_1): S75 - S82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Schildkraut, S. K. Murphy, R. T. Palmieri, E. Iversen, P. G. Moorman, Z. Huang, S. Halabi, B. Calingaert, A. Gusberg, J. R. Marks, et al. Trinucleotide Repeat Polymorphisms in the Androgen Receptor Gene and Risk of Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 473 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Hayes, G. Severi, S. A. Eggleton, E. J.D. Padilla, M. C. Southey, R. L. Sutherland, J. L. Hopper, and G. G. Giles The E211 G>A Androgen Receptor Polymorphism Is Associated with a Decreased Risk of Metastatic Prostate Cancer and Androgenetic Alopecia Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 993 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Brum, P. M. Spritzer, F. Paris, M. A. Maturana, F. Audran, and C. Sultan Association Between Androgen Receptor Gene CAG Repeat Polymorphism and Plasma Testosterone Levels in Postmenopausal Women Reproductive Sciences, February 1, 2005; 12(2): 135 - 141. [Abstract] [PDF]
|
|
|
|
|
|
M. P. Zeegers, L. A.L.M. Kiemeney, A. M. Nieder, and H. Ostrer How Strong Is the Association Between CAG and GGN Repeat Length Polymorphisms in the Androgen Receptor Gene and Prostate Cancer Risk? Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1765 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Keshava, E. C. McCanlies, and A. Weston CYP3A4 Polymorphisms--Potential Risk Factors for Breast and Prostate Cancer: A HuGE Review Am. J. Epidemiol., November 1, 2004; 160(9): 825 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Wang, T. S. Udayakumar, T. S. Vasaitis, A. M. Brodie, and J. D. Fondell Mechanistic Relationship between Androgen Receptor Polyglutamine Tract Truncation and Androgen-dependent Transcriptional Hyperactivity in Prostate Cancer Cells J. Biol. Chem., April 23, 2004; 279(17): 17319 - 17328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Modugno Ovarian Cancer and Polymorphisms in the Androgen and Progesterone Receptor Genes: A HuGE Review Am. J. Epidemiol., February 15, 2004; 159(4): 319 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Y. Liu, A. K. Death, and D. J. Handelsman Androgens and Cardiovascular Disease Endocr. Rev., June 1, 2003; 24(3): 313 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-Z. Liu, H. Wang, and Z. Wang Identification of a Highly Conserved Domain in the Androgen Receptor That Suppresses the DNA-binding Domain-DNA Interactions J. Biol. Chem., April 18, 2003; 278(17): 14956 - 14960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Little, M. J. Khoury, L. Bradley, M. Clyne, M. Gwinn, B. Lin, M.-L. Lindegren, and P. Yoon The Human Genome Project Is Complete. How Do We Develop a Handle for the Pump? Am. J. Epidemiol., April 15, 2003; 157(8): 667 - 673. [Full Text] [PDF]
|
|